|
Demographics
|
|
Male, n (%)
|
32 (91.4)
|
30 (90.9)
|
|
Age, years (SD)
|
27.19 (7.94)
|
28.83 (7.09)
|
|
Disease characteristics
|
|
Symptom duration in years
|
6.76 (5.47)
|
7.98 (4.78)
|
|
Concomitant NSAID, n (%)
|
13 (37.1)
|
15 (45.5)
|
|
Clinical features, n (%)
|
|
Inflammatory back pain
|
32 (91.4)
|
32 (97.0)
|
|
Elevated CRP (>3 mg/liter)
|
31 (88.6)
|
24 (72.7)
|
|
Elevated ESR (male >20; female >15 mm/h)
|
32 (91.4)
|
29 (87.9)
|
|
Disease activity
|
|
ASDAS-CRP
|
3.36 (1.06)
|
3.41 (1.00)
|
|
BASDAI (0–10)
|
4.79 (1.45)
|
4.82 (1.22)
|
|
Total back pain (0–10)
|
5.09 (2.69)
|
5.34 (2.58)
|
|
Global assessment (0–10)
|
5.18 (2.08)
|
5.90 (1.85)
|
|
Swollen joints, range 0–44
|
0.46 (1.48)
|
0.29 (1.1)
|
|
Tender joints, range 0–44
|
5.57 (4.96)
|
4.91 (3.37)
|
|
BASFI (0–10)
|
3.10 (2.00)
|
2.80 (2.00)
|
|
Inflammation/morning stiffness (0–10)
|
4.79 (2.79)
|
5.2 (2.43)
|
|
ESR (mm/h)
|
36.95 (25.26)
|
35.79 (31.46)
|
|
CRP (mg/liter)
|
29.5 (29.93)
|
27.50 (29.69)
|
|
BASMI (0–10)
|
2.88 (1.95)
|
3.75 (1.99)
|
